Cellworks to Present 5
Abstracts at ASH 2021
Cellworks to Present 5 Abstracts at ASH 2021
Cellworks CBM is Predictive of Individual Acute Myeloid Leukemia (AML) Patient Probability of Clinical Response (CR) and Overall Survival (OS): myCare-023
Cellworks CBM predicted Novel Biomarkers for Hyper-CVAD (CVAD) Treatment Response and Combination of Rituximab and Cladribine (RC) in CVAD Resistant Cases of Mantle Cell Lymphoma (MCL)
Cellworks CBM - Based Assessment of Cytarabine (ARA-C) and Anthracycline Response and Novel Biomarker Response Criteria for the Addition of Etoposide (VP16) in Acute Myeloid Leukemia (AML)
Cellworks CBM identifies Immune Modulation As a Key Pathway for Predicting Azacitidine (AZA) Response in Myelodysplastic Syndromes (MDS)
Cellworks CBM identifies Genomic and Molecular Markers for Decitabine (DAC) Plus Valproic-Acid (VPA) Treatment Response in Patients with Myelodysplastic Syndromes (MDS)
90% Therapy Response Prediction Accuracy
A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients.
Read StudyBest of ASH Abstracts 2020
Best of ASH Abstracts 2020
Assessment of Cellworks Omics Biosimulation Therapy Response Predictions for Patients with Acute Myeloid Leukemia (AML) Using Cellworks Singula™: myCare-020-01
Superior Therapy Response Predictions for Patients with Myelodysplastic Syndrome (MDS) Using Cellworks Singula™: myCare-020-02
Predicting Resistance to the Combination of ATO and ATRA in APL Patients with PML-Rara Fusions, Using a Computational Biology Modeling Approach
View how personalized therapy biosimulation works
See the downstream effects when a patient’s
therapy response is biosimulated
Predicting response to treatment with 7+3 in an MDS patient
Predicting response to treatment with Azacitidine + Sorafenib in an AML patient
Cellworks reports include transparent rational
for all predictions
SINGULA™
Predicts personalized response to Standard Care therapies for front-line patients
Download Sample ReportVENTURA™
Predicts and ranks personalized response to combinations of
FDA-approved drugs including off-label and non-oncology drugs for refractory patients
